Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Potent Antitumor Activity of AP24534, An Orally Active Inhibitor of Bcr-Abl, Flt3 and Other Kinases, in Both in Vitro and in Vivo Models of Acute Myeloid Leukemia (AML)

Victor M. Rivera, PhD, Qihong Xu, PhD, Lori Berk, Jeffrey Keats, Scott Wardwell, Frank Wang, PhD, William C. Shakespeare, PhD, Tim Clackson, PhD

Blood (2008) 112 (11): 2932.

https://doi.org/10.1182/blood.V112.11.2932.2932

Published: 2008

Journal Articles

Potent Antitumor Activity of AP24534, an Orally Active Inhibitor of Bcr-Abl Variants Including T315I, in In Vitro and In Vivo Models of Chronic Myeloid Leukemia (CML).

Victor M. Rivera, PhD, Qihong Xu, PhD, Frank Wang, PhD, Joseph Snodgrass, PhD, Thomas O’Hare, PhD, Amie S. Corbin, Jeffrey Keats, Sarah Lamore, Yaoyu Ning, Scott Wardwell, Karin Russian, Marc Broudy, William C. Shakespeare, PhD, Brian J. Druker, MD, John D. Iuliucci, PhD, Tim Clackson, PhD

Blood (2007) 110 (11): 1032.

https://doi.org/10.1182/blood.V110.11.1032.1032

Published: 2007

Journal Articles

Orally Active Inhibitors of the Imatinib Resistant Bcr-Abl Mutant T315I.

Blood (2006) 108 (11): 2180.

https://doi.org/10.1182/blood.V108.11.2180.2180

Published: 2006

Journal Articles

Imatinib-Resistant BCR-ABL Mutant Cellular Screening Paradigm To Characterize Promising Small-Molecule Inhibitors: T315I-BCR-ABL Targeted Drug Discovery.

Mohammad Azam, PhD, William C. Shakespeare, PhD, Chester Metcalf, PhD, Yihan Wang, PhD, Raji Sunderamoorthi, PhD, Xiaotan Zhu, PhD, Wei-Sheng Huang, PhD, Dong Zou, PhD, Mathew Thomas, PhD, Jan Romero, PhD, Jeff Keats, PhD, Qihang Xu, PhD, David Dalgarno, PhD, Tim Clackson, PhD, Tomi K. Sawyer, PhD, George Q. Daley, MD, PhD

Blood (2006) 108 (11): 2181.

https://doi.org/10.1182/blood.V108.11.2181.2181

Published: 2006

Journal Articles

A Potent Src/Abl Kinase Inhibitor (Ap23464) Potently Inhibits the Growth of Myeloid Leukemic Cells Characterized by Flt3-Itd Expression, GM-CSF Dependency, or G-CSF Responsiveness Via an Abl-Independent Mechanism.

Jukka Kanerva, MD, PhD, Ogonna Nwawka, BS, Kevin Hwang, William C. Shakespeare, PhD, Chester A. Metcalf, III, PhD, Tomi K. Sawyer, PhD, Camille L. Bedrosian, MD, Seth J. Corey, MD

Blood (2004) 104 (11): 4479.

https://doi.org/10.1182/blood.V104.11.4479.4479

Published: 2004

NARROW

Potent Antitumor Activity of AP24534, An Orally Active Inhibitor of Bcr-Abl, Flt3 and Other Kinases, in Both in Vitro and in Vivo Models of Acute Myeloid Leukemia (AML)

Potent Antitumor Activity of AP24534, an Orally Active Inhibitor of Bcr-Abl Variants Including T315I, in In Vitro and In Vivo Models of Chronic Myeloid Leukemia (CML).

Orally Active Inhibitors of the Imatinib Resistant Bcr-Abl Mutant T315I.

Imatinib-Resistant BCR-ABL Mutant Cellular Screening Paradigm To Characterize Promising Small-Molecule Inhibitors: T315I-BCR-ABL Targeted Drug Discovery.

A Potent Src/Abl Kinase Inhibitor (Ap23464) Potently Inhibits the Growth of Myeloid Leukemic Cells Characterized by Flt3-Itd Expression, GM-CSF Dependency, or G-CSF Responsiveness Via an Abl-Independent Mechanism.

Email alerts

ASH Publications

American Society of Hematology

Potent Antitumor Activity of AP24534, An Orally Active Inhibitor of Bcr-Abl, Flt3 and Other Kinases, in Both in Vitro and in Vivo Models of Acute Myeloid Leukemia (AML)

Potent Antitumor Activity of AP24534, an Orally Active Inhibitor of Bcr-Abl Variants Including T315I, in In Vitro and In Vivo Models of Chronic Myeloid Leukemia (CML).

Orally Active Inhibitors of the Imatinib Resistant Bcr-Abl Mutant T315I.

Imatinib-Resistant BCR-ABL Mutant Cellular Screening Paradigm To Characterize Promising Small-Molecule Inhibitors: T315I-BCR-ABL Targeted Drug Discovery.

A Potent Src/Abl Kinase Inhibitor (Ap23464) Potently Inhibits the Growth of Myeloid Leukemic Cells Characterized by Flt3-Itd Expression, GM-CSF Dependency, or G-CSF Responsiveness Via an Abl-Independent Mechanism.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only